Bausch Health Companies Raises FY2026 Sales Guidance from $10.670B-$10.920B to $10.790B-$11.040B vs $10.773B Est

This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold

Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Bausch Health Companies stock surged nearly 40% in July 2026, driven by a regulatory win in Canada for its Prokedi schizophrenia drug and a strong Q2 earnings beat. The company reported $2.85 billion in revenue (13% YoY growth) and adjusted net income of $476 million ($1.26 per share), exceeding analyst expectations. Management raised full-year 2026 guidance for both revenue and adjusted EBITDA, citing strength across its diversified pharmaceutical portfolio.

8-K filing — Bausch Health Companies Inc. (BHC)

Filed: 2026-07-29 AccNo: 0000885590-26-000105 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Bausch Health Companies Q2 Adj. EPS $1.26 Beats $1.06 Estimate, Sales $2.852B Beat $2.679B Estimate

Bausch Health, Canada, Completes Negotiations With pan-Canadian Pharmaceutical Alliance Resulting In LOI For PrOKEDI 75mg And 100mg, Long-Acting Injectable Antipsychotic Agent For Schizophrenia Treatment

Bausch Health And Solta Medical Announce Thermage Awarded AAA Well-Known Trademark Certification By China Trademark Association

Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026